Not exactly. Colorectal cancer is one of 17 different types of cancer rising for Gen X and Millennials, according to American ...

Jenna Fischer, 50, said in an Instagram post sharing her breast cancer journey: "My tumor was so small it could not be felt on a physical exam. If I had waited six months longer, things could have ...

More than $500,000 was expected to be raised for the American Cancer Society. The walk is a celebration of courage and hope and a movement that unites communities to end breast cancer, according ...

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and where cancer metastasizes. A new randomized controlled trial out of ...

Breast cancer has been a formidable health challenge across generations, impacting 2.3 million women globally in 2022 alone. However, decades of dedicated research have gradually transformed this ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Verzenio remains the only drug in the CDK4/6 class to be approved for adjuvant use in early breast cancer, which has helped it to buoyant sales growth, up 84% to nearly $2.5 billion last year.

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...